Literature DB >> 28701390

Spontaneous Closure of Patent Ductus Arteriosus in Infants ≤1500 g.

Jana Semberova1,2, Jan Sirc2,3, Jan Miletin4,2,3,5, Jachym Kucera2, Ivan Berka2, Sylva Sebkova2, Sinead O'Sullivan1, Orla Franklin6, Zbynek Stranak2,3.   

Abstract

OBJECTIVES: Patent ductus arteriosus (PDA) remains a challenging issue in very low birth weight (VLBW) infants, and its management varies widely. Our aim in this study was to document the natural course of ductus arteriosus in a cohort of VLBW infants who underwent conservative PDA management with no medical or surgical intervention.
METHODS: A retrospective cohort study conducted in 2 European level-3 neonatal units.
RESULTS: A total of 368 VLBW infants were born within the study period. Two hundred and ninety-seven infants were free of congenital malformations or heart defects and survived to hospital discharge. Out of those, 280 infants received truly conservative PDA management. In 237 (85%) of nontreated infants, the PDA closed before hospital discharge. The Kaplan-Meier model was used to document the incidence proportion of PDA closure over time for different gestational age groups. The median time to ductal closure was 71, 13, 8, and 6 days in <26+0, 26+0 to 27+6, 28+0 to 29+6, and ≥30 weeks, respectively. For different birth weight groups, the median was 48, 22, 9, and 8 days in infants weighing <750, 750 to 999, 1000 to 1249, and 1250 to 1500 g, respectively. No statistically significant relationship was found between PDA closure before hospital discharge and neonatal morbidities.
CONCLUSIONS: The likelihood of PDA spontaneous closure in VLBW infants is extremely high. We provide in our findings a platform for future placebo-controlled trials focused on the smallest and youngest infants.
Copyright © 2017 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2017        PMID: 28701390     DOI: 10.1542/peds.2016-4258

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  25 in total

1.  Prophylactic Indomethacin in extremely preterm infants: association with death or BPD and observed early serum creatinine levels.

Authors:  Hibo H Abdi; Carl H Backes; Molly K Ball; Maria M Talavera-Barber; Mark A Klebanoff; Sudarshan R Jadcherla; Tahagod H Mohamed; Jonathan L Slaughter
Journal:  J Perinatol       Date:  2021-03-04       Impact factor: 2.521

Review 2.  The ductus arteriosus in neonates with critical congenital heart disease.

Authors:  Craig R Wheeler; Shawn Sen; Philip T Levy
Journal:  J Perinatol       Date:  2022-07-15       Impact factor: 3.225

Review 3.  Patent Ductus Arteriosus of the Preterm Infant.

Authors:  Shannon E G Hamrick; Hannes Sallmon; Allison T Rose; Diego Porras; Elaine L Shelton; Jeff Reese; Georg Hansmann
Journal:  Pediatrics       Date:  2020-11       Impact factor: 7.124

Review 4.  Does crossover treatment of control subjects invalidate results of randomized trials of patent ductus arteriosus treatment?

Authors:  Meera N Sankar; William E Benitz
Journal:  J Perinatol       Date:  2020-10-06       Impact factor: 2.521

5.  Indomethacin for symptomatic patent ductus arteriosus in preterm infants.

Authors:  Peter Evans; Deirdre O'Reilly; Jonathan N Flyer; Roger Soll; Souvik Mitra
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

6.  Outcomes in infants < 29 weeks of gestation following single-dose prophylactic indomethacin.

Authors:  Jeff Reese; Nathalie L Maitre; Maria Gillam-Krakauer; James C Slaughter; Robert B Cotton; Blaine E Robinson
Journal:  J Perinatol       Date:  2020-09-18       Impact factor: 2.521

7.  Natural evolution of ductus arteriosus with noninterventional conservative management in extremely preterm infants born at 23-28 weeks of gestation.

Authors:  Se In Sung; Yun Sil Chang; Jisook Kim; Jin Hwa Choi; So Yoon Ahn; Won Soon Park
Journal:  PLoS One       Date:  2019-02-13       Impact factor: 3.240

8.  Early prediction of spontaneous Patent Ductus Arteriosus (PDA) closure and PDA-associated outcomes: a prospective cohort investigation.

Authors:  Jonathan L Slaughter; Clifford L Cua; Jennifer L Notestine; Brian K Rivera; Laura Marzec; Erinn M Hade; Nathalie L Maitre; Mark A Klebanoff; Megan Ilgenfritz; Vi T Le; Dennis J Lewandowski; Carl H Backes
Journal:  BMC Pediatr       Date:  2019-09-13       Impact factor: 2.125

9.  Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial).

Authors:  Tim Hundscheid; Wes Onland; Bart van Overmeire; Peter Dijk; Anton H L C van Kaam; Koen P Dijkman; Elisabeth M W Kooi; Eduardo Villamor; André A Kroon; Remco Visser; Daniel C Vijlbrief; Susanne M de Tollenaer; Filip Cools; David van Laere; Anne-Britt Johansson; Catheline Hocq; Alexandra Zecic; Eddy Adang; Rogier Donders; Willem de Vries; Arno F J van Heijst; Willem P de Boode
Journal:  BMC Pediatr       Date:  2018-08-04       Impact factor: 2.125

10.  PDA: Does it matter?

Authors:  Jalal M Abu-Shaweesh; Eyad Almidani
Journal:  Int J Pediatr Adolesc Med       Date:  2019-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.